Crossmark

S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study

Crossref DOI link: https://doi.org/10.1007/s40268-019-0265-0

Published Online: 2019-03-01

Published Print: 2019-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Venerito, Marino https://orcid.org/0000-0001-8581-0974
License Information

Text and Data Mining valid from 2019-03-01
More Information

Article History

First Online: 1 March 2019

Compliance with Ethical Standards

:

: Nordic Pharma provided financial assistance for the preparation of this article. The patient data collection was managed by an independent party Quanta-Medical (France), supported by Nordic Pharma.

: Marino Venerito received honoraria from Merck Serono, Bayer Vital, and Sirtex and is a member of the advisory boards of Ipsen, Lilly, Nordic Pharma, BMS, MSD, and Amgen.

: The study was approved by the institutional review board and/or ethics committee at each participating center and was in accordance with the Helsinki Declaration of 1975, as revised in 1983.